Thee, S. | Search bioRxiv

bioRxiv2024

Systemic effects of cystic fibrosis transmembrane conductance regulator (CFTR) modulators on the blood proteome

Cystic fibrosis (CF), resulting from a dysfunction in the cystic fibrosis transmembrane conductance regulator (CFTR), affects multiple organs through mucus obstruction and differences in secretion. The CFTR modulator drug combination elexacaftor/tezacaftor/ivacaftor (ELX/TEZ/IVA, ETI) has markedly improved clinical symptoms, but its broader molecular and systemic effects remain to be fully elucidated. We employed mass spectrometry-based proteomics to compare the blood proteomes of CF patients treated with the earlier, less effective lumacaftor/ivacaftor (LUM/IVA) combination against those receiving the more potent ELX/TEZ/IVA therapy. Our analysis revealed both specific and common pharmacodynamic signatures associated with inflammation and metabolic processes under each treatment regimen. Notably, ELX/TEZ/IVA therapy exhibited more consistent alterations across patients that were directed towards profiles observed in healthy individuals. Furthermore, by comparing sputum and blood proteomes of ELX/TEZ/IVA treated patients we identified counter-directional changes in the pulmonary surfactant-associated protein B, SFTPB, a potential biomarker of lung tissue repair, which also correlated with lung function improvements. This study provides a comprehensive resource that enhances our understanding of CFTR modulator-driven proteome alterations, offering insights to both systemic and local protein regulation in CF. Our findings indicate that ELX/TEZ/IVA promotes broader systemic health improvements, providing critical insights that could shape future therapeutic strategies in CF.

molecular biology↗

bioRxiv2023

Myeloperoxidase-dependent tyrosine halogenation potentiates alpha-defensins functions

Neutrophils are immune cells that eliminate microbes using a powerful arsenal of reactive oxygen species, hypohalous acids, proteases, and antimicrobial peptides -- yet how these cytotoxic effectors act in concert remains poorly understood. Here, we identify an unrecognized synergy between oxidative and non-oxidative neutrophil defenses. We show that myeloperoxidase-derived hypohalous acids selectively halogenate -defensins (HNP1-3) at conserved tyrosine residues. This post-translational modification occurs in both human and rat neutrophils and is prominent in diseases marked by neutrophil-rich inflammation, including cystic fibrosis, bacterial pneumonia, and Staphylococcus aureus abscesses. Halogenation increases HNP1 hydrophobicity without altering its structure, reprogramming these peptides into potent immunomodulatory mediators. Using single-cell transcriptomics and a in vivo peritonitis model, we demonstrate that halogenated HNP1s amplify immune signaling. Our analysis of the human haloproteome reveals a novel oxidative mechanism by which hypohalous acids rewire immune protein functions, uncovering an unexpected layer of cooperation between neutrophil effector systems. The discovery of halogenated HNP1s represents, to our knowledge, the first characterization of a protein halogenation that has biologically significance in human immunity.

biochemistry↗